Epstein-Barr virus-DNA load monitoring late after lung transplantation: A surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression

Transplantation

Volumn 83, Issue 4, 2007, Pages 433-438

  Bakker, Nicolaas A ^a   Verschuuren, Erik A M ^a   Erasmus, Michiel E ^a   Hepkema, Bouke G ^a   Veeger, Nic J G M ^a   Kallenberg, Cees G M ^a   Van Der Bij, Wim ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Epstein Barr virus; Immunosuppression; Lung transplantation; Posttransplant lymphoproliferative disease

Indexed keywords

ACICLOVIR; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIGEN PP65; FOSCARNET; FOSCARNET SODIUM; GANCICLOVIR; LYMFOGLOBULINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; THYMOGOBULIN; UNCLASSIFIED DRUG; VALACICLOVIR; VIRUS DNA; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADD ON THERAPY; ADULT; AGED; ARTICLE; BRONCHIOLITIS OBLITERANS; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PATIENT MONITORING; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REACTIVATION; ACUTE DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL PROTOCOL; DISEASE COURSE; GENETICS; GRAFT REJECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOLOGY; RISK FACTOR; STANDARD; SURVIVAL RATE; TIME; VIROLOGY; VIRUS INFECTION;

ACUTE DISEASE; ADULT; AGED; BIOLOGICAL MARKERS; BRONCHIOLITIS OBLITERANS; CLINICAL PROTOCOLS; DISEASE PROGRESSION; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GRAFT REJECTION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 33947536947     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000252784.60159.96     Document Type: Article

References (24)

1. Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report-2005. J Heart Lung Transplant 2005; 24: 956.
2. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222.
3. Nalesnik MA. The diverse pathology of post-transplant lymphoproliferative disorders: the importance of a standardized approach. Transpl Infect Dis 2001; 3: 88.
4. Tanner JE, Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis 2001; 3: 60.
5. Deleted in proof.
6. Deleted in proof.
7. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723.
8. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346.
9. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4: 87.
10. Savoie A, Perpete C, Carpentier L, et al. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994; 83: 2715.
11. Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994; 84: 972.
12. Wagner HJ, Fischer L, Jabs WJ, et al. Longitudinal analysis of Epstein-Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by real-time polymerase chain reaction. Transplantation 2002; 74: 656.
13. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97: 1165.
14. McDiarmid SV, Jordan S, Kim GS, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 1604.
15. Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005; 5: 2222.
16. Cooper JD, Billingham M, Egan T, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993; 12: 713.
17. van der Bij W, Torensma R, van Son WJ, et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes. J Med Virol 1988; 25: 179.
18. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996; 15: 1.
19. Malouf MA, Chhajed PN, Hopkins P, et al. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 2002; 21: 547.
20. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997; 14: 8.
21. Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTL). Blood 2006; 108: 2942.
22. Smets F, Sokal EM. Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management. Pediatr Transplant 2002; 6: 280.
23. Smets F, Latinne D, Bazin H, et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002; 73: 1603.
24. Axelrod DA, Holmes R, Thomas SE, Magee JC. Limitations of EBV-PCR monitoring to detect EBV associated post-transplant lymphoproliferative disorder. Pediatr Transplant 2003; 7: 223.